Proteolix initiates Phase I study of carfilzomib

Texas Accelerated Research is participating in the study under the leadership of Dr Kyriakos Papadopoulos. This trial would be evaluating single agent carfilzomib, a novel proteasome inhibitor, in patients with recurrent or advanced solid tumors.

The Phase Ib portion of the study is a dose-escalation study designed to determine the maximum tolerated dose of carfilzomib administered intravenously in patients with solid tumors. After determining the maximum tolerated dose, additional patients will be enrolled in Phase II and stratified according to disease type, including non-small cell lung cancer, small cell lung cancer, ovarian cancer and renal cancer.

Dr Papadopoulos said: “We are very excited about beginning this study in San Antonio. This next generation proteasome inhibitor has shown promising activity in myeloma and will offer a new option to our patients with advanced cancer.”